Biotechnology
22 articles on Biotechnology, researched and written by the Shotlee Editorial Team from primary sources.
InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as CEO Ahead of Non-Injectable Peptide Platform Launch
InstaMed Pharmaceuticals, a pioneer in needle-free peptide delivery, has appointed Tracy Gibbs, PhD, as its new Chief Executive Officer. This leadership change comes as the company gears up for the August 3rd global launch of its groundbreaking oral dissolving peptide film platform, offering a convenient alternative to traditional injections.
9 min read
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
Ozempic, Mounjaro & More: Yale Study Exposes Risky Online GLP-1 Prescribing
New research from Yale University highlights critical gaps in the online prescribing of GLP-1 medications, raising serious concerns about patient safety and regulatory oversight.
8 min read
Peptides and Health: The Truth Behind the Beauty and Weight Loss Claims
Peptides are the newest buzzword in health and beauty, promising everything from wrinkle reduction to profound weight loss. But does the science actually back up the claims, and are they safe?
7 min read
Beyond Ozempic: New Muscle-Burning Pill Reshaping Diabetes Care
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
6 min read
Retatrutide: The Next Wave in Metabolic Peptide Therapy?
Discover Retatrutide, a groundbreaking peptide with triple-receptor activity, poised to redefine metabolic health and weight management strategies. Learn about its science, potential, and what it means for the future of wellness.
8 min read
Wegovy & Mounjaro Boom Fuels Peptide Production Surge for GLP-1 Drugs
The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.
7 min read
GLP-1 Drugs: Understanding the Weight Loss Revolution
The advent of GLP-1 receptor agonists has transformed the landscape of weight management, offering new hope for individuals struggling with obesity. This article delves into the science, benefits, potential drawbacks, and the leading players in this groundbreaking field.
7 min read
Eli Lilly 150 Years: AI, GLP-1 Advances & Future of Weight Loss
Eli Lilly celebrates 150 years with a focus on AI-driven manufacturing, new GLP-1 oral therapies, and expanded neuroscience research, signaling a major shift in pharmaceutical innovation.
8 min read
GLP-1 Drugs Fuel Surge in Whey Protein Demand: Industry Response
The massive adoption of GLP-1 receptor agonists for weight management is creating a significant ripple effect across the food industry, specifically driving an intense surge in demand for high-quality, muscle-preserving protein sources like whey. Dairy producers are scrambling to meet this new market reality.
6 min read
Oral GLP-1 Drugs: A New Era for Weight Management in India
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
7 min read
Peptide Therapy & The Biohacking Boom: Navigating Unregulated Wellness
The world of biohacking is increasingly embracing peptides, but what's the reality behind the hype? This article delves into the science, the risks of unregulated substances, and the potential impact of regulatory changes on access to these compounds.
10 min read
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production
Eli Lilly is set to invest a substantial $3 billion in China over the next decade to bolster the production of its groundbreaking oral GLP-1 receptor agonist, Orforglipron. This strategic move aims to enhance supply chain capacity for a drug poised to treat type 2 diabetes and obesity.
8 min read
Study Explores Plant-Based Platform for Oral GLP-1 Therapies
A pioneering study led by Henry Daniell at Penn Dental Medicine has engineered lettuce chloroplasts to produce functional exenatide and lixisenatide, offering a plant-based path to oral GLP-1 therapies. This approach addresses key barriers like stomach degradation and high costs, potentially transforming diabetes and obesity treatment. Patients may soon swap weekly injections for simple lettuce-based pills.
6 min read
$3,000 Minipigs Powering Europe's Drug Pipeline
In eastern Denmark, Ellegaard Gottingen Minipigs A/S breeds specialized $3,000 minipigs vital to Europe's drug pipeline, including Novo Nordisk's Ozempic and Wegovy. These biosecure facilities address supply chain vulnerabilities exposed by the pandemic's monkey shortages. As the EU pushes for biotech independence, these smaller, human-like pigs offer a strategic alternative.
6 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
Viking Therapeutics Stock Surges on VK2735 Trial Success
Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.
1 min read
Peptide Therapeutics Market to Hit USD 82.19 Billion by 2032 Amid Rising Demand for Oncology Medicines: SNS Insider
The global Peptide Therapeutics Market is experiencing substantial growth, projected to reach USD 82.19 billion by 2032. This expansion is fueled by the increasing need for specialized medications, particularly in oncology and metabolic diseases. The U.S. market is expected to reach USD 35.71 billion by 2032.
4 min read
Chinese Pharmaceutical Sector on the Verge of Global Expansion
China's pharmaceutical industry is rapidly ascending on the global stage, fueled by innovation and strategic alliances with Western companies. This rise presents both opportunities and challenges as China aims to become a major player in drug discovery and development.
7 min read
Scientists Develop Method to Reprogram Pancreas for GLP-1 Production Without Ozempic
Scientists are exploring a way to enable the body's own production of glucagon-like peptide-1 (GLP-1), the hormone mimicked by weight-loss drugs. Two biotech startups are developing gene therapies to reprogram cells to produce GLP-1, potentially replacing regular injections.
3 min read
Oral Proteins & Peptides Market to Reach USD 47.2 Billion Globally by 2035, Exhibiting 15.3% CAGR - TMR Study
The global market for oral proteins and peptides is experiencing rapid expansion, with projections estimating a value of US$ 47.2 billion by 2035. This growth, driven by increasing demand for peptide-based therapeutics and advancements in delivery technologies, signifies a dynamic shift in the pharmaceutical and nutraceutical landscape.
6 min read